Author

S. J. Hogg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

R. W. Johnstone· 3 shared C. J. Kearney· 2 shared S. J. Vervoort· 2 shared A. C. Lewis· 1 shared A. Paehler· 1 shared A. Ruefli-Brasse· 1 shared A. Wei· 1 shared B. F. Cravatt· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. W. Johnstone

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Covalent Targeting of Splicing in T Cells.

K. A. Scott, H. Kojima, N. Ropek, C. D. Warren, T. L. Zhang, S. J. Hogg, C. Webster, X. Zhang, J. Rahman, B. Melillo, B. F. Cravatt, J. Lyu, O. Abdel-Wahab, E. V. Vinogradova

This study develops chemical probes to target splicing factors in T cells, showing state-dependent loss of ITK via SF3B1 and demonstrating covalent ligandability of splicing regulators.

bioRxiv · Dec 18, 2023Immunology

Inhibition of pyrimidine biosynthesis targets protein translation in AML.

L. M. Kats, J. So, A. C. Lewis, L. K. Smith, K. Stanley, L. Pijpers, P. Dominguez, S. J. Hogg, S. Vervoort, R. W. Johnstone, G. McDonald, D. B. Ulanet, J. Murtie, E. Gruber

This study shows that DHODH inhibitors block protein translation in AML by reducing YY1 and enhance AML treatment while sparing normal blood cells.

bioRxiv · Sep 24, 2021 · PreprintCancer Biology

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

L. C. Wellinger, S. J. Hogg, D. M. Newman, T. Friess, D. Geiss, J. Michie, K. M. Ramsbottom, M. Bacac, T. Fauti, D. Marbach, L. Jarassier, P. Thienger, A. Paehler, L. A. Cluse, C. J. Kearney, , R. W. Johnstone

This paper identifies BET bromodomain inhibitors as agents that enhance anti-tumor immunity by sensitizing tumors to TNF-mediated cytotoxicity through suppression of NF-κB signaling.

bioRxiv · Feb 15, 2021Cancer Biology

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit

J. Salmon, I. Todorovski, S. J. Vervoort, K. L. Stanley, C. J. Kearney, L. Martelotto, F. Rossello, T. Semple, G. Mir Arnau, M. Zethoven, M. Bots, E. Vidacs, K. McArthur, E. Gressier, N. De Weerd, , R. W. Johnstone

The paper shows that inhibiting HDACs in AML promotes type I IFN production by pDCs, enhancing anti-tumor immunity and therapeutic benefit.

bioRxiv · Aug 23, 2020 · PreprintCancer Biology